The menace of progressive cardiac systolic dysfunction and sudden cardiac death(SCD)still hover threateningly over the patient with heart failure.Despite available phagnlacological treatment is utilized.it is still proven lowly effective in the prevention of SCD caused by fatal ventricular arrhythmia.Data from AHA indicated that evaluation and management of patients at risk for SCD (primary prevention)has higher efficacy in reducing mortality than secondary prevention.Unfortunately,present risk stratifiers,such as HRV,QT interval dispersion and late potential testing,does not offer accurate and timely alarms in primary prevention of SCD.Nowadays,randomized muhicenter trials(AVID、CASH、CIDS)and clinical practice have proven t11at conventional implantable cardioverter defibrillator(ICD)implantation has become the standard even optimal treatment in the secondary prevention for SCD.Is primary prophylactic ICD therapy for SCD in patients with heart failure eriective?Positive results from MADIT Ⅱ trial seems gi

作者：黄从新

来源：中华心律失常学杂志 2009 年 13卷 4期